Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT07682454
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Hepatocellular Carcinoma (HCC)
  • Liver Cancer, Adult

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Parenchymal Blood Volume (PBV) Imaging — PROCEDURE
    Undergo imaging
  • Nitroglycerin — DRUG
    Given Intra-Arterially
  • Medical Record Review — OTHER
    Data will be collected from the participant medical records.

Study Details

This is a single-arm, open-label, single-center, first-in-human feasibility study evaluating parenchymal blood volume (PBV) imaging as a tool to dynamically assess perfusional changes in hepatocellular carcinoma (HCC) potentiated by intra-arterial administration of nitroglycerin.

Key Dates

Start date
Aug 1, 2026
Status verified
May 2026
Primary completion
Feb 1, 2029
Completion
Feb 1, 2030

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Nitroglycerin Injection
    Participants with confirmed hepatocellular carcinoma (HCC) will undergo parenchymal blood volume (PBV) imaging before and after intra-arterial nitroglycerin injection during standard transarterial chemoembolization (TACE) treatment. Nitroglycerin doses ranging from 200-300 micrograms will be administered based on patient body mass index (BMI) and interventional radiology standards. Participants will be followed either in person or via telehealth on days 3, 7, 30, and 90 for safety and post-procedural assessment, until withdrawal from the study or death, whichever occurs first.

Primary Outcome Measure

Proportion of Participants with >= 30% increase in Tumoral Blood Volume [ Time Frame: Day 1 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143
Diana Flores
[email protected]
415-514-6221
[email protected]
877-827-3222
Christopher Brunson, MD (PRINCIPAL_INVESTIGATOR)
Zuckerberg San Francisco General Hospital (ZSFG)San FranciscoCalifornia94110
Diana Flores
[email protected]
415-514-6221
[email protected]
877-827-3222
Christopher Brunson, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
University of California, San Francisco· San Francisco, CAZuckerberg San Francisco General Hospital (ZSFG)· San Francisco, CA

Related Studies